Mitotane

Mitotane

Clinical data
Pregnancy category	C
Routes of administration	oral (500mg tablets)
ATC code	L01XX23 (WHO)
Legal status
Legal status	presciption required
Pharmacokinetic data
Bioavailability	40%
Protein binding	6%
Elimination half-life	18 to 159 days
Identifiers
IUPAC name 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)-ethyl]-benzene
CAS Number	53-19-0
PubChem CID	4211
DrugBank	APRD00494
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H10Cl4
Molar mass	320.04 g/mol

WikiDoc Resources for Mitotane
Articles
Most recent articles on Mitotane Most cited articles on Mitotane Review articles on Mitotane Articles on Mitotane in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mitotane Images of Mitotane Photos of Mitotane Podcasts & MP3s on Mitotane Videos on Mitotane
Evidence Based Medicine
Cochrane Collaboration on Mitotane Bandolier on Mitotane TRIP on Mitotane
Clinical Trials
Ongoing Trials on Mitotane at Clinical Trials.gov Trial results on Mitotane Clinical Trials on Mitotane at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mitotane NICE Guidance on Mitotane NHS PRODIGY Guidance FDA on Mitotane CDC on Mitotane
Books
Books on Mitotane
News
Mitotane in the news Be alerted to news on Mitotane News trends on Mitotane
Commentary
Blogs on Mitotane
Definitions
Definitions of Mitotane
Patient Resources / Community
Patient resources on Mitotane Discussion groups on Mitotane Patient Handouts on Mitotane Directions to Hospitals Treating Mitotane Risk calculators and risk factors for Mitotane
Healthcare Provider Resources
Symptoms of Mitotane Causes & Risk Factors for Mitotane Diagnostic studies for Mitotane Treatment of Mitotane
Continuing Medical Education (CME)
CME Programs on Mitotane
International
Mitotane en Espanol Mitotane en Francais
Business
Mitotane in the Marketplace Patents on Mitotane
Experimental / Informatics
List of terms related to Mitotane

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Mitotane, or o,p'-DDD, is a medication used in the treatment of the rare disease adrenocortical carcinoma. It is an isomere chemically to DDT and is a derivative of DDD.

It has been produced by Bristol Myers Squibb SpA but it is marketed as an orphan drug due to the small number of patients in need of it. Its administration occurs in cases where the tumour cannot be surgically omitted. A 2007 study of 177 patients shows a significant increase in the recurrence-free interval after radical surgery followed by Mitotane when compared to surgery alone.

Mitotane alternates steroides peripheral metabolism, represses directly the adrenal cortex and alternates cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).

Its trade name is Lysodren.

Veterinary use

Mitotane is also used to treat pituitary-dependent Cushing's syndrome in canines. The medication is used in the controlled destruction of adrenal tissue, leading to a decrease in cortisol production.

External links

• FDA Label
• V. P. Komissarenko1, I. S. Chelnakova and A. S. Mikosha. “Effect of o,p-dichlorodiphenyldichloroethane and perthane in vitro on glutathione reductase activity in the adrenals of dogs and guinea pigs.”